These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 31490820)

  • 21. Idarucizumab: A Review as a Reversal Agent for Dabigatran.
    Syed YY
    Am J Cardiovasc Drugs; 2016 Aug; 16(4):297-304. PubMed ID: 27388764
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of Age and Renal Function on Idarucizumab Pharmacokinetics and Idarucizumab-Mediated Reversal of Dabigatran Anticoagulant Activity in a Randomized, Double-Blind, Crossover Phase Ib Study.
    Glund S; Stangier J; van Ryn J; Schmohl M; Moschetti V; Haazen W; De Smet M; Gansser D; Norris S; Lang B; Reilly P; Kreuzer J
    Clin Pharmacokinet; 2017 Jan; 56(1):41-54. PubMed ID: 27317414
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lessons learnt from local real-life experience with idarucizumab for the reversal of dabigatran.
    Brennan Y; Favaloro EJ; Pasalic L; Keenan H; Curnow J
    Intern Med J; 2019 Jan; 49(1):59-65. PubMed ID: 29869387
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Idarucizumab for Reversal of Dabigatran-Associated Anticoagulation.
    Yogaratnam D; Ditch K; Medeiros K; Doyno C; Fong JJ
    Ann Pharmacother; 2016 Oct; 50(10):847-54. PubMed ID: 27389324
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Idarucizumab for Dabigatran Reversal.
    Pollack CV; Reilly PA; Eikelboom J; Glund S; Verhamme P; Bernstein RA; Dubiel R; Huisman MV; Hylek EM; Kamphuisen PW; Kreuzer J; Levy JH; Sellke FW; Stangier J; Steiner T; Wang B; Kam CW; Weitz JI
    N Engl J Med; 2015 Aug; 373(6):511-20. PubMed ID: 26095746
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of four direct oral anticoagulants on rotational thromboelastometry (ROTEM).
    Seyve L; Richarme C; Polack B; Marlu R
    Int J Lab Hematol; 2018 Feb; 40(1):84-93. PubMed ID: 28980758
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Spotlight on idarucizumab and its potential for the reversal of anticoagulant effects of dabigatran.
    Sié P
    Drug Des Devel Ther; 2016; 10():1683-9. PubMed ID: 27274201
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The use of frozen plasma samples in thromboelastometry.
    Schoergenhofer C; Buchtele N; Schwameis M; Bartko J; Jilma B; Jilma-Stohlawetz P
    Clin Exp Med; 2017 Nov; 17(4):489-497. PubMed ID: 28210886
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evidence supporting idarucizumab for the reversal of dabigatran.
    Pollack CV
    Am J Emerg Med; 2016 Nov; 34(11S):33-38. PubMed ID: 27697436
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Incomplete responses to the recommended dose of idarucizumab: a systematic review and pharmacokinetic analysis.
    Athavale A; Jamshidi N; Roberts DM
    Clin Toxicol (Phila); 2020 Aug; 58(8):789-800. PubMed ID: 32267185
    [No Abstract]   [Full Text] [Related]  

  • 31. Dose requirements for idarucizumab reversal of dabigatran in a lethal porcine trauma model with continuous bleeding.
    Honickel M; Spronk HM; Rossaint R; Stoppe C; van Ryn J; Ten Cate H; Grottke O
    Thromb Haemost; 2017 Jun; 117(7):1370-1378. PubMed ID: 28424818
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Idarucizumab for Reversing Dabigatran-Induced Anticoagulation: A Systematic Review.
    Thibault N; Morrill AM; Willett KC
    Am J Ther; 2018; 25(3):e333-e338. PubMed ID: 27175894
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Idarucizumab, a specific reversal agent for dabigatran: mode of action, pharmacokinetics and pharmacodynamics, and safety and efficacy in phase 1 subjects.
    Reilly PA; van Ryn J; Grottke O; Glund S; Stangier J
    Am J Emerg Med; 2016 Nov; 34(11S):26-32. PubMed ID: 27707528
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The in vitro addition of idarucizumab to plasma samples from patients increases thrombin generation.
    Božič Mijovski M; Malmström RE; Vene N; Antovic JP; Mavri A
    Sci Rep; 2021 Mar; 11(1):5920. PubMed ID: 33723299
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Late rebound of dabigatran levels after idarucizumab reversal in two patients with severe renal failure.
    Stecher A; Vene N; Mavri A; Mijovski MB; Krevel B; Gradišek P
    Eur J Anaesthesiol; 2017 Jun; 34(6):400-402. PubMed ID: 28459790
    [No Abstract]   [Full Text] [Related]  

  • 36. Idarucizumab (Praxbind)--an antidote for dabigatran.
    Med Lett Drugs Ther; 2015 Nov; 57(1482):157-8. PubMed ID: 26583604
    [No Abstract]   [Full Text] [Related]  

  • 37. Comparison of thromboelastometry (ROTEM®) with standard plasmatic coagulation testing in paediatric surgery.
    Haas T; Spielmann N; Mauch J; Madjdpour C; Speer O; Schmugge M; Weiss M
    Br J Anaesth; 2012 Jan; 108(1):36-41. PubMed ID: 22086509
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The recommended dose of idarucizumab may not always be sufficient for sustained reversal of dabigatran.
    Simon A; Domanovits H; Ay C; Sengoelge G; Levy JH; Spiel AO
    J Thromb Haemost; 2017 Jul; 15(7):1317-1321. PubMed ID: 28426914
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [The first use of iv. idarucizumab for dabigatran reversal in Hungary].
    Driesz L; Barabás É; Bodócs I; Szántó Z; Herr G; Bencsik G; Pál L; Borbola J
    Orv Hetil; 2017 Mar; 158(10):387-392. PubMed ID: 28270004
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of the immunogenicity of the dabigatran reversal agent idarucizumab during Phase I studies.
    Norris S; Ramael S; Ikushima I; Haazen W; Harada A; Moschetti V; Imazu S; Reilly PA; Lang B; Stangier J; Glund S
    Br J Clin Pharmacol; 2017 Aug; 83(8):1815-1825. PubMed ID: 28230262
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.